title: Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies.
authors.forename: C
authors.initials: C
authors.lastname: Gambacorti-Passerini
authors.forename: M
authors.initials: M
authors.lastname: Gasser
authors.forename: S
authors.initials: S
authors.lastname: Ahmed
authors.forename: S
authors.initials: S
authors.lastname: Assouline
authors.forename: L
authors.initials: L
authors.lastname: Scapozza
mesh_terms: D003198:Computer Simulation; D000069439:Dasatinib; D008958:Models, Molecular; D011485:Protein Binding / Q000187:drug effects; D011487:Protein Conformation; D047428:Protein Kinase Inhibitors / Q000737:chemistry* / Q000494:pharmacology; D017434:Protein Structure, Tertiary; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000737:chemistry*; D016315:Proto-Oncogene Proteins c-abl / Q000037:antagonists & inhibitors / Q000737:chemistry*; D011743:Pyrimidines / Q000737:chemistry* / Q000494:pharmacology; D013329:Structure-Activity Relationship; D013844:Thiazoles / Q000737:chemistry* / Q000494:pharmacology
chemical_list: D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D011505:Protein-Tyrosine Kinases; D016315:Proto-Oncogene Proteins c-abl; D000069439:Dasatinib